US stock · Healthcare sector · Drug Manufacturers—General
Company Logo

Pfizer Inc.

PFENYSE

38.36

USD
+0.34
(+0.89%)
Market Closed
7.30P/E
11Forward P/E
0.35P/E to S&P500
216.554BMarket CAP
4.23%Div Yield
Upcoming Earnings
26 Jul-31 Jul
Shares Short
5/15/23
45.92M
Short % of Float
0.81%
Short % of Shares Outs.
0.81%
% Held by Insiders
0.03%
% Held by Institutions
70.67%
Beta
0.59
PEG Ratio
-0.76
52w. high/low
54.93/36.17
Avg. Daily Volume
22.46M
Return %
Stock
S&P 500
1 year
(22.83)
(9.05)
3 years
26.34
50.26
5 years
8.94
38.50
Scale: |
High
Low
24.24
14.26
18.99
11.62
20.36
14.00
21.90
16.63
26.09
20.75
32.50
25.33
33.12
27.51
36.46
28.47
37.39
28.25
37.35
30.90
46.47
33.20
44.56
33.97
43.08
27.88
61.71
33.36
58.55
41.45
51.60
39.23
Currency: USD
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
Revenue per share
7.00
7.18
7.14
8.44
8.63
7.93
7.57
7.82
7.91
8.68
8.80
9.14
9.29
7.54
14.51
17.89
Earnings per share
1.18
1.20
1.23
1.03
1.28
1.96
3.23
1.44
1.13
1.18
3.57
1.90
2.92
1.73
3.92
5.59
FCF per share
1.66
2.46
2.20
1.24
2.38
2.11
2.39
2.41
2.11
2.28
2.39
2.32
1.79
2.09
5.33
4.64
Dividends per share
1.15
1.27
0.79
0.76
0.80
0.88
0.97
1.04
1.12
1.20
1.28
1.36
1.44
1.52
1.56
0.71
CAPEX per share
0.27
0.25
0.17
0.19
0.21
0.18
0.22
0.25
0.24
0.33
0.37
0.37
0.47
0.50
0.48
0.58
Book Value per sh.
9.40
8.56
12.85
10.93
10.51
10.92
11.20
11.24
10.48
9.78
11.94
10.80
11.34
11.38
13.78
17.06
Comm.Shares outs.
6,917
6,727
7,007
8,036
7,817
7,442
6,813
6,346
6,176
6,089
5,970
5,872
5,569
5,555
5,601
5,608
Avg. annual P/E ratio
21.4
16.0
12.7
16.4
15.2
11.9
9.0
21.1
29.7
27.6
9.5
20.6
13.6
21.2
10.7
8.9
P/E to S&P500
1.2
0.7
0.2
0.8
0.9
0.8
0.5
1.2
1.5
1.2
0.4
0.8
0.6
0.6
0.4
0.4
Avg. annual div. yield
4.6%
6.6%
5.1%
4.5%
4.1%
3.8%
3.3%
3.4%
3.4%
3.7%
3.8%
3.5%
3.6%
4.1%
3.7%
1.4%
Revenue (m)
48,418
48,296
50,009
67,809
67,425
58,986
51,584
49,605
48,851
52,824
52,546
53,647
51,750
41,908
81,288
100,330
Operating margin
21.3%
31.1%
31.3%
20.9%
27.0%
30.5%
31.7%
27.2%
26.6%
26.0%
26.8%
28.0%
26.9%
20.9%
24.9%
37.1%
Depreciation (m)
5,200
5,090
4,757
8,487
9,026
7,611
6,410
5,537
5,157
5,757
6,269
6,384
6,010
4,777
5,191
3,609
Net profit (m)
8,144
8,104
8,635
8,257
10,009
14,570
22,003
9,135
6,960
7,215
21,308
11,153
16,273
9,616
21,979
31,372
Income tax rate
11.0%
17.0%
20.3%
11.9%
31.5%
21.2%
27.4%
25.5%
22.2%
13.4%
(73.5)%
5.9%
7.8%
6.4%
7.6%
9.6%
Net profit margin
16.8%
16.8%
17.3%
12.2%
14.8%
24.7%
42.7%
18.4%
14.2%
13.7%
40.6%
20.8%
31.4%
22.9%
27.0%
31.3%
Working capital (m)
25,014
16,067
24,445
31,859
29,659
32,796
32,878
36,071
14,405
7,834
10,714
18,068
(4,501)
9,147
17,022
9,121
Long-term debt (m)
7,314
7,963
43,193
38,410
34,931
31,036
30,462
31,541
28,818
31,398
32,666
32,429
35,955
35,571
34,757
32,884
Equity (m)
65,010
57,556
90,014
87,813
82,190
81,260
76,307
71,301
64,720
59,544
71,308
63,407
63,143
63,238
77,201
95,661
ROIC
8.7%
9.6%
5.5%
5.9%
6.7%
9.4%
13.6%
6.9%
5.7%
5.9%
16.6%
9.7%
13.6%
8.4%
16.8%
21.0%
Return on capital
8.0%
8.8%
5.7%
5.7%
8.4%
10.1%
16.1%
8.1%
6.1%
5.6%
7.9%
8.3%
11.5%
7.5%
13.9%
18.2%
Return on equity
12.5%
14.1%
9.6%
9.4%
12.2%
17.9%
28.8%
12.8%
10.8%
12.1%
29.9%
17.6%
25.8%
15.2%
28.5%
32.8%
Plowback ratio
2.1%
(5.4)%
35.7%
26.3%
37.7%
55.2%
70.1%
27.7%
0.3%
(1.4)%
64.1%
28.5%
50.6%
12.2%
60.3%
87.4%
Div.&Repurch./FCF
152.6%
54.2%
36.1%
71.3%
82.0%
93.9%
140.3%
75.9%
100.6%
88.6%
88.8%
148.0%
169.2%
72.7%
29.2%
22.9%
Capital Structure
23 Feb · 2023 | Q4
All numbers in millions
Total liabilities
$ 101,288
Total assets
$ 197,205
Long-term debt
$ 32,884
Cash and equiv.
$ 416
Goodwill
$ 51,375
Retained earnings
$ 125,656
Common stock
5,615
Enterprise Value
$ 249,022
Working Capital
Currency: USD, in millions
2020
2021
2022
Cash & Investments
12,221
31,069
22,732
Receivables
11,194
15,745
10,952
Inventory
8,046
9,059
8,981
Other
3,606
3,980
7,226
Current assets
35,067
59,693
51,259
Acc. Payable
4,309
5,578
6,809
Debt due
2,703
2,241
2,945
Other
18,908
34,852
32,384
Current liabilities
25,920
42,671
42,138
Annual growth rates
(avg. rate of change)
1 year
5 years
10 years
Revenue
23.43%
23.71%
11.02%
Cash flow
(12.85)%
33.47%
13.09%
Earnings
42.74%
44.08%
27.26%
Dividends
(54.63)%
(11.36)%
(2.86)%
Book value
23.91%
11.43%
3.40%
Insider Trading
Type
Shares
Date
Damico Jennifer B.
InKind
1,427
02/27/23
Mcdermott Michael
InKind
3,081
02/27/23
Damico Jennifer B.
Exempt
11,150
02/25/23
Damico Jennifer B.
InKind
4,958
02/25/23
Damico Jennifer B.
InKind
2,233
02/25/23
Quarterly Revenue
Currency: USD, in millions
Year
1Q
2Q
3Q
4Q
Total
2020
12,028
11,801
12,131
5,947
41,907
2021
14,582
18,977
24,094
23,635
81,288
2022
25,661
27,742
22,638
24,290
100,331
Earnings per share
Currency: USD
Year
1Q
2Q
3Q
4Q
Total
2020
0.61
0.62
0.39
0.11
1.73
2021
0.87
0.99
1.45
0.61
3.92
2022
1.40
1.77
1.53
0.89
5.59
Quarterly dividends paid
Currency: USD
Year
1Q
2Q
3Q
4Q
Total
2020
0.38
0.38
0.38
0.38
1.52
2021
0.39
0.39
0.39
0.39
1.56
2022
0.40
0.40
0.40
0.50
1.70
Company Description
Sector:
Healthcare
Industry:
Drug Manufacturers—General
CEO:
Dr. Albert Bourla D.V.M., DVM, Ph.D.
Full-time employees:
79,000
City:
New York
Address:
235 East 42nd Street
IPO:
Jan 17, 1944
Website:
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Recent News
· 13 Mar, 2023 · The Wall Street Journal
· 13 Mar, 2023 · The Wall Street Journal
· 27 Feb, 2023 · The Wall Street Journal
· 31 Jan, 2023 · The Wall Street Journal
· 30 Dec, 2022 · The Wall Street Journal
· 31 Oct, 2022 · The Wall Street Journal
· 23 Sep, 2022 · The Wall Street Journal
· 31 Aug, 2022 · The Wall Street Journal
· 28 Aug, 2022 · The Wall Street Journal
· 26 Aug, 2022 · The Wall Street Journal
· 23 Aug, 2022 · The Wall Street Journal
· 22 Aug, 2022 · The Wall Street Journal
· 5 Aug, 2022 · The Wall Street Journal
· 28 Jul, 2022 · The Wall Street Journal
· 26 Jul, 2022 · The Wall Street Journal
· 8 Jul, 2022 · The Wall Street Journal
· 30 Jun, 2022 · The Wall Street Journal
· 29 Jun, 2022 · The Wall Street Journal
· 18 Jun, 2022 · The Wall Street Journal
· 12 Jun, 2022 · The Wall Street Journal
· 24 May, 2022 · The Wall Street Journal